

September 15, 2010



U.S. Patent Office Issues MultiStat(R) Patent for Treatment of Rosacea

GAINESVILLE, Fla., Sept. 15, 2010 (GLOBE NEWSWIRE) -- Quick-Med Technologies, Inc. (OTCBB:QMDT), a life sciences company that is developing innovative technologies for the healthcare and consumer markets, announced today that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent No. 7,795,302 entitled "Use of Compositions for Treating Rosacea." The patent is part of a portfolio that Quick-Med has licensed from the University of Michigan and extends the growing intellectual property coverage of the Company's MultiStat^(R) family of compounds.

"This new patent covering methods for treating Rosacea with our MultiStat technology is yet another significant expansion that strengthens the IP estate under our licensing agreement with the University of Michigan," said J. Ladd Greeno, Quick-Med's CEO. "Although an estimated 16 million Americans currently suffer from rosacea, the treatments available today often create unwanted side effects, including skin redness and irritation. MultiStat is shown to promote the maintenance, healing and repair of the inflamed skin, and may be combined with existing medications to deliver more effective, better tolerated treatments."

The patent issued covers methods for treating rosacea with an antimicrobial, a retinoid, and an inhibitor of toll-like receptors in both topical and oral applications. The broad range of antimicrobials to be utilized in combination with the MultiStat family includes tetracycline, erythromycin, azithromycin, clarithromycin, milbemycin, aminoglycoside, penicillin (optimally in combination with a beta-lactamase inhibitor), cephalosporin, fluoroquinolone, streptogramin and sulfanamide.

About MultiStat^(R)

MultiStat is Quick-Med's family of patented matrix metalloproteinase inhibitors (MMPis),

which have been shown to be highly effective in reducing skin wrinkling and aging. The MultiStat family consists of 10 patented compounds, patented formulae for developing other compounds, numerous use or method patents and other intellectual property involving the use of MMP inhibition techniques in skin therapy. These MMPis, which have been proven effective in broad-based applications, including improving the appearance of fine lines and wrinkles associated with natural aging or sun-induced premature aging and damage, are marketed to the cosmetics industry as performance ingredients in commercially available anti-aging creams. Quick-Med currently owns or has exclusive licenses for topical uses of MultiStat compounds for cosmetic and military applications.

About Rosacea

Rosacea is a chronic skin condition involving inflammation of the cheeks, nose, chin, forehead, or eyelids. It may appear as redness, prominent spider-like blood vessels, swelling, or skin eruptions similar to acne. According to the National Rosacea Society an estimated 16 million Americans currently suffer from rosacea.

About Quick-Med Technologies, Inc.

Quick-Med Technologies, Inc. is a life sciences company that is developing innovative technologies for the consumer and healthcare markets. In addition to commercializing MultiStat, the Company is developing advanced antimicrobial technologies for infection prevention and control. Its NIMBUS^(R) technology is the first FDA-cleared, non-leaching antimicrobial available in a wound dressing. Its NimbuDerm(TM) technology is being developed as a persistent hand sanitizer and its new *Stay Fresh*(TM) technology provides highly durable antimicrobial protection for apparel and other textile applications. For more information, see: www.quickmedtech.com.

(C) 2010 Quick-Med Technologies, Inc. All rights reserved. MultiStat^(R) and NIMBUS^(R) are registered trademarks and *Stay Fresh*(TM) is a trademark of Quick-Med Technologies, Inc.

Forward-looking statements (statements which are not historical facts) in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained in this release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may", "will", "to", "expect", "plan", "believe", "anticipate", "intend", "could", "would", "estimate", and/or "continue" or the negative or other variations thereof or comparable terminology are intended to identify forward-looking statements involve risks and uncertainties, including those risks that are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"), which may be accessed at the SEC's Edgar System at www.sec.gov.

Contact:

Quick-Med Technologies
J. Ladd Greeno, CEO

(888) 835.2211 Ext 102
lgreeno@quickmedtech.com
The Ruth Group

Media:

Eric Reiss
(646) 536-7032
ereiss@theruthgroup.com

Investors:

Ashleigh Barreto
(646) 536-7028
abarreto@theruthgroup.com